Print

Purpose

Researchers are looking for new ways to treat people with certain advanced solid tumors. Advanced means the cancer has spread to other parts of the body and cannot be removed with surgery. Solid tumors are cancers mostly in body organs and tissues, not in the blood or other body liquids. The main goal of this study is to learn about the safety of MK-3120 and if people tolerate it.

Conditions

Eligibility

Eligible Ages
Over 18 Years
Eligible Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Has a confirmed advanced (unresectable and/or metastatic) solid tumor and has received or been intolerant to all available treatments - If human immunodeficiency virus (HIV) positive, has well controlled HIV on antiretroviral therapy (ART) - If hepatitis B surface antigen (HBsAg) positive, must have received hepatitis B virus (HBV) antiviral therapy for at least 4 weeks and have undetectable HBV viral load - If hepatitis C virus (HCV) infected, must have undetectable HCV viral load

Exclusion Criteria

  • Has active inflammatory bowel disease requiring immunosuppressive medication or previous history of inflammatory bowel disease - Has uncontrolled significant cardiovascular disease or cerebrovascular disease - Has history of documented severe dry eye syndrome, severe Meibomian gland disease and/or blepharitis, or severe corneal disease that prevents/delays corneal healing - Has pleural effusion, ascites, and/or pericardial effusion that are symptomatic or require repeated drainage - Is HIV-positive and has a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease - Known additional malignancy that is progressing or has required active treatment within the past 2 years - Known active central nervous system (CNS) metastases and/or carcinomatous meningitis - Active infection requiring systemic therapy, with exceptions - History of (noninfectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease - Has HBV or HCV infection

Study Design

Phase
Phase 1/Phase 2
Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel Assignment
Primary Purpose
Treatment
Masking
None (Open Label)

Arm Groups

ArmDescriptionAssigned Intervention
Experimental
Arm 1 Dose level 1 		Participants receive MK-3120 at dose level 1 as per the schedule specified in the arm.
  • Biological: MK-3120
    IV infusion
    Other names:
    • SKB410
Experimental
Arm 2 Dose level 2 		Participants receive MK-3120 at dose level 2 as per the schedule specified in the arm.
  • Biological: MK-3120
    IV infusion
    Other names:
    • SKB410

Recruiting Locations

The University of Alabama at Birmingham ( Site 1005)
Birmingham, Alabama 35249
Contact:
Study Coordinator
205-934-4199

University of Miami Hospital and Clinics, Sylvester Cancer Center ( Site 1003)
Miami, Florida 33136
Contact:
Study Coordinator
305-243-5302

John Theurer Cancer Center at Hackensack University Medical Center ( Site 1009)
Hackensack, New Jersey 07601
Contact:
Study Coordinator
551-996-5900

NEXT Oncology ( Site 1010)
Austin, Texas 78758
Contact:
Study Coordinator
737-610-5202

NEXT Oncology ( Site 1011)
Houston, Texas 77054
Contact:
Study Coordinator
832-384-7912

NEXT Oncology ( Site 1012)
Irving, Texas 75039
Contact:
Study Coordinator
972-893-8800

Virginia Commonwealth University ( Site 1008)
Richmond, Virginia 23219
Contact:
Study Coordinator
804-828-7999

More Details

Status
Recruiting
Sponsor
Merck Sharp & Dohme LLC

Study Contact

Toll Free Number
1-888-577-8839
Trialsites@msd.com

Notice

Study information shown on this site is derived from ClinicalTrials.gov (a public registry operated by the National Institutes of Health). The listing of studies provided is not certain to be all studies for which you might be eligible. Furthermore, study eligibility requirements can be difficult to understand and may change over time, so it is wise to speak with your medical care provider and individual research study teams when making decisions related to participation.